Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07343960 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
A Phase 1 study of Moderate Hepatic Impairment, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT07343960: Recruiting Phase 1 study of Moderate Hepatic Impairment, sponsored by AstraZeneca.
NCT07343960 is a Phase 1 study of Moderate Hepatic Impairment that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 20 participants, roughly in line with the 21-participant average among 4 other Moderate Hepatic Impairment trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07343960, a Phase 1 study of Moderate Hepatic Impairment, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to measure the pharmacokinetics (PK), safety, and tolerability of capivasertib in participants with moderate hepatic impairment and participants with normal hepatic function (as control).
Primary Outcome
To compare the PK (AUCinf) of a single oral dose of capivasertib in participants with moderate hepatic impairment to participants with normal hepatic function.
Conditions Studied
Interventions
- DRUG Capivasertib
Study Locations (2)
California
- Research Site - Rialto
Texas
- Research Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-06 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 1 |
What NCT07343960 shows while recruiting
NCT07343960 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, roughly in line with the 21-participant average among 4 other Moderate Hepatic Impairment trials with a reported enrollment target.
The record links to 1 condition, with Moderate Hepatic Impairment appearing as the primary indexed condition, and to 1 intervention - of which Capivasertib is the first listed.
NCT07343960 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT07343960 about?
NCT07343960 is a clinical study titled "A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment". The purpose of this study is to measure the pharmacokinetics (PK), safety, and tolerability of capivasertib in participants with moderate hepatic impairment and participants with normal hepatic function (as control).
What is the current status of trial NCT07343960?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-01-06. Estimated completion is 2026-07-31.
What conditions does trial NCT07343960 study?
This clinical trial studies the following conditions: Moderate Hepatic Impairment.
What interventions are being tested in trial NCT07343960?
The interventions under investigation include: Capivasertib (DRUG).
Who is sponsoring clinical trial NCT07343960?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07343960 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate Hepatic Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
RECRUITING · Phase 1
-
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
COMPLETED · Phase 1
-
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
COMPLETED · Phase 1
-
A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI